Journey Medical Corporation to Present at the 34th Annual ROTH Conference
March 09, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation
February 11, 2022 08:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
January 13, 2022 07:00 ET
|
Journey Medical Corporation
Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition...
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
December 10, 2021 08:00 ET
|
Journey Medical Corporation
Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10,...
Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference
December 07, 2021 16:05 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Introduces Expanded Board of Directors
November 29, 2021 08:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded...
Journey Medical Corporation Announces Closing of Initial Public Offering
November 16, 2021 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Prices $35.2 Million Initial Public Offering
November 12, 2021 07:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces Launch of its Initial Public Offering
November 08, 2021 10:12 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization...
Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank
April 05, 2021 07:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...